China
Africa
Explore chapters and articles related to this topic
Miscellaneous Drugs during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Inflammatory bowel disease includes ulcerative colitis and Crohn’s disease (regional enteritis) of unknown etiology. Corticosteroids (i.e., prednisone) have been used for the active stages of both diseases (Box 15.9). Sulfasalazine and 5-aminosalicylic acid were successfully used to treat ulcerative colitis during pregnancy (Habal et al., 1993). Refractory cases of Ulcerative colitis and Crohn’s disease during pregnancy refractory to corticosteroid therapy are an indication for immunosuppressive drugs, (e.g., azathioprine, 6-mercaptopurine). Meta-analysis of azathioprine/6-mercaptopurine to treat Crohn’s disease found that both drugs were efficacious for treatment of active disease and remission maintenance (Pearson et al., 1995). However, efficacy during pregnancy was not studied. Inflammatory bowel disease treatments (Box 15.9) include cyclosporine for Crohn’s disease (Brynskov et al., 1989). More potent immunosuppressants (e.g., azathioprine, 6-mercaptopurine, cyclosporine) should be reserved for pregnant women refractory to steroid therapy. The best possible maternal health is the most important milestone in optimizing child health and continuing medical therapy in IBD during pregnancy. The benefit of efficacious maternal treatment with non-teratogenic medication outweighs possible risks under most circumstances (Restellini et al., 2020).
Neuromuscular Junction Disorders
Published in Philip B. Gorelick, Fernando D. Testai, Graeme J. Hankey, Joanna M. Wardlaw, Hankey's Clinical Neurology, 2020
Diana Mnatsakanova, Qin Li Jiang
Prednisone is the most commonly used immune-directed therapy: Induces marked improvement or remission in >70% of patients.10,11Typically, started at a high daily dose (0.75–1.0 mg/kg/day) and gradually tapered off over months or continued at a low daily or alternate-day dose.
Hyperthyroidism
Published in Pallavi Iyer, Herbert Chen, Thyroid and Parathyroid Disorders in Children, 2020
In adults, it has been shown that progression of ophthalmopathy can be prevented by treatment with prednisone for 3 months following 131I therapy. Adjunctive prednisone therapy is not routinely recommended for most children, as most do not have significant eye disease. The prolonged administration of prednisone is also associated with growth failure, weight gain, and immune suppression. Nevertheless, prednisone (0.5 mg/kg × 4–6 weeks) may be useful for the child who has moderate or severe eye disease and will be treated with 131I.
Efficacy and safety of azathioprine plus prednisone versus prednisone alone as first-line treatment for antinuclear antibody-positive immune thrombocytopenia: a retrospective cohort study
Published in Hematology, 2023
Junnan Su, Meihong Xu, Zhigao Dong, Qingqing Wang, Lili Ma, Pingping Xiao, Xuyan Chen
Importantly, the comparison of safety between first-line AZA plus prednisone and prednisone alone in ANA-positive ITP patients is rarely reported. The present study discovered that the incidence of all adverse events was not different between ANA-positive ITP patients receiving AZA plus prednisone and those receiving prednisone alone as first-line treatment. This finding indicated that first-line AZA plus prednisone had a good safety profile for ANA-positive ITP patients. In addition, the common adverse events induced by AZA are leucopenia, anemia, and hepatobiliary laboratory abnormalities in ITP patients according to a previous study [14]. The prevalent adverse events caused by prednisone are a cushingoid appearance, weight gain, hypertension, hyperglycemia, insomnia, and dizziness in ITP patients [32]. The present study discovered that common adverse events caused by first-line AZA plus prednisone were pneumonia (13.3%), anemia (13.3%), cough (13.3%), nausea (6.7%), and granulocytopenia (6.7%) in ANA-positive ITP patients, which were partly in line with previous studies [14, 32]; meanwhile, no new adverse events occurred. Taken together, AZA plus prednisone as a first-line treatment might be safe and tolerable for ANA-positive ITP patients.
Psychometric properties and predictive validity of the PP-ACT
Published in Journal of Asthma, 2023
James A. Shepperd,, Gregory D. Webster, Gabrielle C. Pogge, David Fedele,, Sreekala Prabhakaran, Jean Hunleth,, Erika A. Waters
Participants reported at both Time 1 and Time 2 the frequency of asthma exacerbations in the past three months via three items: “In the past 3 months, how many times did your child have so much trouble breathing that: (1) they continue to have asthma symptoms even after they use their “quick relief” medicine (albuterol through a nebulizer or inhaler)?; (2) they needed to go to urgent care or the emergency room?; (3) they needed to take a short course of an oral steroid pill or liquid like prednisone? Note: Prednisone is a prescription corticosteroid that reduces inflammation. People take it for 3–7 days in a row to treat serious asthma episodes.” (1 = never in the past 3 months, 2 = once, 3 = twice, 4 = three times, 5 = four or more times). Because we used these items as indicators for latent variables in subsequent analyses, they were neither summed nor averaged.
Astilbin improves pregnancy outcome in rats with recurrent spontaneous abortion by regulating Th1/Th2 balance
Published in Immunopharmacology and Immunotoxicology, 2022
Ying Qian, Yue Pei, Wei Jiang, Caihong Zheng
Prednisone is a synthetic corticosteroid used to treat or prevent different conditions during pregnancy, including autoimmune diseases. Prednisone has been shown to reduce the incidence of RSA and obstetric complications. Low-dose glucocorticoid treatment can inhibit T cells and natural killer cells, improve fertilization rate, and slow the development of immune disease. Prednisolone (5–20 mg per day) has been shown to improve pregnancy outcome in several studies [19]. The prevalence of prednisone use in the first trimester is approximately 1.3%, making prednisone one of the most commonly used drugs during early pregnancy. However, the short-term use of prednisone is associated with maternal and fetal complications such as preterm delivery. Moreover, the risk of preterm delivery and low birth weight is increased in patients with autoimmune diseases [20]. Therefore, the development of new immunomodulatory drugs for clinical applications is urgently needed.